MedCision

09/21/2017

Engineering T Cell therapies with Automated Technologies https://goo.gl/N6w53L

09/19/2017

MedCision CEO Rolf Ehrhardt, along with representatives from TrakCel, Adaptimmune, Cellex and TiGenix, will be participating in a panelist discussion on alleviating the impact of costly, time consuming cell therapy supply chains on industry, payer and patient alike. Don't miss this special programming at Cell and Gene Therapy Europe on Thursday at 16:05.

09/07/2017

ThawSTAR® CB Automated Cryobag Thawing System at Summit

09/07/2017

On September 7, 2016, Nicole Gularte received experimental CAR-T therapy for ALL. Today, September 7, 2017, Nicole inspires her audience of CAR-T professionals at CAR-TCR Summit.

09/06/2017

MedCision will present data on our ThawSTAR automated cell thawing systems at this evening's poster session. See you at poster #2 at 4:05pm.

09/06/2017

We're just getting started here at CAR-TCR Boston. Stop by booth 29 at the exhibit hall entrance to see our ThawSTAR CB automated cryobag thawing system in action.

08/30/2017

We will be attending CAR-TCR Summit 2017 next week in Boston. Enjoy this short interview with our Chief Commercial Officer, Sam Kent, where he discusses last year's experience. Attending the show this year? Stop by Booth 29 or view our poster presentation at Space #2.

Introducing: CAR-TCR Interview Shorts Series The next in the CAR-TCR Summit Interview Shorts Series is an interview with Samuel Kent, SVP, Business...

08/28/2017

MedCision participated as a founding member on the Phacilitate Automation Special Interest Group steering committee. Chief Commercial Officer, Samuel Kent, is featured as a session moderator in the recently-released Rapporteur's Report for the event. https://goo.gl/C81LtH

08/24/2017

In a recent independent study, Canadian scientists cite use of the ThawSTAR® automated cell thawing platform in their research on how transient warming events affect mesenchymal stromal cell functionality. https://goo.gl/Hyw2CL

08/17/2017

We are delighted to support RepliCel Life Sciences, an innovative regenerative medicine company, in their trials. https://goo.gl/2PcpLL RepliCel Life Sciences Joins MedCision’s ThawSTAR® Early Adopter Program

RepliCel Regenerative Medicine Company to Adopt ThawSTAR® Cell Thawing Systems to De-Risk Cell Therapy Clinical Trial

08/14/2017

We are pleased to be featured in RegMedNet's Spotlight on Commercialization and Translation. Read about ThawSTAR and the science of cell thawing in Brave new world: Automation, thawing, and connectivity will drive the success of cellular therapy https://goo.gl/EBae61

Controlled automated thawing of therapeutic cells is important to ensuring their optimal viability, recovery, as well as safeguarding cell health...

07/26/2017

Our latest peer-reviewed publication on key innovations driving cell therapy post-production technologies forward https://goo.gl/XrPVRK